ANI Pharma (NASDAQ: ANIP) reported Q3 EPS of $0.66, $0.20 better than the analyst estimate of $0.46. Revenue for the quarter came in at $17.4 million versus the consensus estimate of $14.6 million.

Arthur S. Przybyl, President and CEO, stated,

"ANI had a record third quarter across all major metrics of revenue, EBITDA, operating income, and earnings per share. Our third quarter financial results were the direct result of continued organic revenue growth, combined with the revenues from Lithobid and Vancocin, products we acquired in the third quarter. Third quarter results include two months of revenue from Vancocin and its authorized generic. We expect to launch Vancocin under our own label in the fourth quarter. We continue to advance our internal generic product development efforts while selectively pursuing acquisitions and partnerships for late stage ANDA products and mature brands."

ANI Pharma sees Q4 2014 EPS of $0.60-$0.65, versus the consensus of $0.45. ANI Pharma sees Q4 2014 revenue of $17-18 million, versus the consensus of $15.2 million.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.